CureVac N.V. (NASDAQ:CVAC) Q3 2022 Earnings Call Transcript

Franz-Werner Haas: That’s really early to say. It’s also an entirely different approach. You have to keep that in mind, right, because if it’s off the shelf, and of course scalability is favorable. But if it’s required for efficacy, then one needs to go fully personalized and time will tell.

Unidentified Analyst: Thanks.

Operator: We have a follow up from Roy Buchanan with JMP. Please proceed.

Roy Buchanan: Hi, great. Thanks for taking the follow up. Appreciate the detailed timing for the COVID and flu trials in the first quarter. I’m just wondering if you have a sense of which one might read out first.

Franz-Werner Haas: That’s a very good question. We cannot say because the recruitment is not fully finalized here. And therefore it’s very hard to say, very hard to say. But we hope that everything will come close, that we will have a complete readout. But as I said, the recruitment, especially if you go then in the elderly, this will take — there’s a certain sequence of events on the recruitment. This is exactly what will decide on the timelines here. And as it is not completed yet, it’s very hard to say.

Roy Buchanan: Okay, got it. And then a detailed question I guess on the workflow on Slide 18. You have fill and finish grade out. I assume that’s because that’s not relevant in the personal vaccine setting or is there some other reason. Can you just explain that? Thanks.

Franz-Werner Haas: You are asking about their workflow in Slide 18. Yes, so the timing there is that the sample is taken and within two weeks, we can go from the sample to design of the vaccine. And then, of course, it needs to be manufactured and quality controlled. And in reasonable clinical practice that should be done within six to eight weeks at max, which is what we’re currently working on. As you have been referring to the fill and finish, this is exactly where the printer should play a role that then you have got everything at the same spot. And then in the small scales, the fill and finish should not be a limiting factor here either.

Roy Buchanan: Okay, got it. Thank you.

Operator: Thank you. At this time, I would like to turn the call back over to management for closing comments.

Sarah Fakih: With this, we would like to conclude this conference call. Thank you very much for your participation.